Skip to main content

Table 3 Antipsychotics taken by subjects including those in the incidence study at baseline and endpoint

From: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

Medications Number (%) of subjects taking at baseline (N = 44) Number of subjects lost to follow-up (N = 9) Number (%) of subjects taking at endpoint (N = 35)a
High-potency conventional antipsychoticsb 12 (27.3) 2 4 (11.4)
Medium-potency conventional antipsychoticsc 4 (9.1) 1 4 (11.4)
Low-potency conventional antipsychoticsd 5 (11.4) 2 5 (14.3)
Clozapine 5 (11.4) 2 7 (20.0)
Olanzapine 3 (6.8) 1 5 (14.3)
Risperidone 14 (31.8) 1 13 (37.1)
Sertindole 1 (2.3) 0 12 (34.3)
  1. aIncluding 7 patients developing metabolic syndrome and 28 patients not developing metabolic syndrome.
  2. bHigh-potency conventional antipsychotics including haloperidol and trifluoperazine.
  3. cMedium-potency conventional antipsychotics including clopenthixol and perphenazine.
  4. dLow-potency conventional antipsychotics including chlorpromazine and thioridazine.